Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA.
Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Clin Exp Ophthalmol. 2018 Apr;46(3):247-259. doi: 10.1111/ceo.13022. Epub 2017 Aug 31.
This novel endpoint tracks functional vision changes in patients with inherited retinal dystrophies (IRDs) over time.
The aims of the study were to determine whether a multi-luminance mobility test (MLMT) can detect functional vision changes over time in subjects with IRDs and to assess natural history and potential effects of investigational agents.
This is a prospective, observational study.
Sixty-two subjects were enrolled. Sixty (29 normal sighted and 31 visually impaired) were eligible; 54 (28 visually impaired and 26 normal-sighted) completed all testing visits.
Subjects navigated MLMT courses three times over 1 year. At each visit, subjects completed testing using individual eyes, and both eyes, at up to nine standardized, increasing luminance levels (range 1 to 400 lux). Accuracy and speed were evaluated and compared with visual acuity (VA), visual field (VF) and a visual function questionnaire.
Accuracy and speed of normal and visually impaired subjects on MLMT, and reliability and content validity of MLMT were the main outcome measures.
MLMT distinguished normal-sighted from visually impaired subjects. All control subjects passed all MLMT attempts at all tested light levels. Visually impaired subjects' performance varied widely; some declined over 1 year. Performance declined markedly below certain VA and VF thresholds. Concordance on performance on two baseline visits was high: correlations for accuracy were 94% and 98% for lowest common and highest common lux levels.
MLMT differentiated visually impaired from control populations and, in visually impaired subjects, identified a range of performances; and tracked performance declines over time, consistent with these progressive conditions.
本新型终点可追踪遗传性视网膜疾病(IRD)患者的功能视力随时间的变化。
本研究旨在确定多亮度移动测试(MLMT)是否能在IRD 患者随时间推移检测到功能视力变化,并评估自然史和研究药物的潜在影响。
这是一项前瞻性、观察性研究。
共纳入 62 名受试者。60 名(29 名视力正常和 31 名视力障碍)符合入选条件;54 名(28 名视力障碍和 26 名视力正常)完成了所有测试访视。
受试者在 1 年内进行了 3 次 MLMT 测试。每次访视,受试者使用单眼和双眼,在最多 9 个标准化的、递增亮度水平(范围 1 至 400 lux)下完成测试。评估准确性和速度,并与视力(VA)、视野(VF)和视觉功能问卷进行比较。
MLMT 中正常视力和视力障碍受试者的准确性和速度,以及 MLMT 的可靠性和内容效度是主要结果测量。
MLMT 区分了视力正常和视力障碍的受试者。所有对照受试者均通过了所有 MLMT 尝试,达到了所有测试的光强度。视力障碍受试者的表现差异很大;一些人在 1 年内下降。在某些 VA 和 VF 阈值以下,表现明显下降。两次基线访视的表现一致性很高:最低和最高共同 lux 水平的准确性相关性分别为 94%和 98%。
MLMT 区分了视力障碍和对照人群,在视力障碍受试者中,识别了一系列表现;并随时间追踪到表现下降,与这些进行性疾病一致。